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he global burden of inﬂ  uenza 
on morbidity and mortality 
is considerable, with an 
estimated 1 million annual deaths 
worldwide [1]. In temperate regions, 
there are clear seasonal variations in 
the occurrence of inﬂ  uenza, with a 
marked peak in cold winter months 
[2]. In contrast, seasonality is less 
deﬁ  ned in tropical regions—here, 
there is high background inﬂ  uenza 
activity throughout the year, on top of 
which epidemics occur at intermediate 
months between the inﬂ  uenza season 
in temperate countries of the Northern 
and Southern hemispheres. Inﬂ  uenza 
seasonal patterns in the Americas are 
summarized in Figure 1, which illustrates 
the transition between the Northern 
and Southern hemispheres. Very little 
is known about exactly how and why 
the seasonality of inﬂ  uenza varies with 
latitude. No link with environmental 
conditions has been convincingly shown, 
although inﬂ  uenza activity appears to 
coincide with the rainy season in some 
tropical countries [3]. 
    Until very recently, the impact of 
inﬂ  uenza on health was believed to be 
insigniﬁ  cant in tropical regions. But 
this impression may be changing, in 
part thanks to the recent studies by 
Joseph S. M. Peiris and his colleagues 
from Hong Kong, one of which appears 
in this issue of   PLoS Medicine   [4]. Hong 
Kong is a subtropical city located 
within the likely epicenter of pandemic 
inﬂ  uenza in Southeast Asia [5].
    Methods for Estimating the Burden 
of Inﬂ  uenza
    Estimating the burden of inﬂ  uenza 
on hospitalizations and deaths is not 
straightforward in temperate countries, 
and it is even less so in tropical countries 
[2]. Severe clinical outcomes are often 
caused by secondary bacterial infections, 
and a primary inﬂ  uenza infection 
may be unrecognized. Additionally, 
laboratory conﬁ  rmation of inﬂ  uenza 
infection is rarely conducted. As a result, 
most inﬂ  uenza-related hospitalizations 
and deaths are not attributed to 
inﬂ  uenza on discharge forms and death 
certiﬁ  cates, and statistical methods are 
necessary to assess the true burden of 
inﬂ  uenza on health.
    Traditionally, for temperate 
countries, the impact of a particular 
inﬂ  uenza epidemic is estimated 
as the number of “excess deaths” 
or “excess cases” above a seasonal 
baseline. This approach relies on 
identifying periods without inﬂ  uenza 
activity to generate a model baseline 
of expected winter deaths (or cases) 
[6–8]. But the approach fails in 
tropical regions, where there is no 
well-deﬁ  ned non-inﬂ  uenza period 
(Figure 1). An alternative method 
recently developed by the United 
States Centers for Disease Control uses 
virus surveillance data to guide models 
of burden, assuming a proportional 
relation between virus activity and the 
number of hospitalization or deaths 
attributable to inﬂ  uenza [9,10]. For the 
US, both traditional and new methods 
produced very similar estimates of 
inﬂ  uenza mortality burden (Table 
1 and [11,12]). In their Hong Kong 
study, Peiris et al. appropriately used a 
variation of the virus-guided modeling 
approach by linking weekly hospital 
discharges with weekly prevalence of 
inﬂ  uenza virus in respiratory specimens 
sampled in the community [4].
  Inﬂ  uenza Burden is Broadly Similar 
in Hong Kong and the US
    Peiris et al. found that the annual 
inﬂ  uenza-related hospitalization 
rates are quite similar in Hong Kong 
and temperate countries (Table 1), 
conﬁ  rming their earlier studies [13,14]. 
In Hong Kong, as in many other 
countries, the impact of inﬂ  uenza 
is seen not only on pneumonia and 
inﬂ  uenza outcomes [12,15], but also 
on a wider range of chronic health 
conditions such as diabetes and 
cardiovascular diseases [12,15]. Peiris 
et al. also report that inﬂ  uenza-related 
hospitalization rates vary with age as a 
U-shaped curve, where young infants 
and elderly are at highest risk of severe 
disease outcome, reminiscent of the 
age pattern of interpandemic inﬂ  uenza 
in the US and other temperate 
countries. However, one difference 
between Hong Kong and US children 
stands out: these authors had shown 
in a previous hospital cohort study 
that young children in Hong Kong 
had a hospitalization rate that was 
roughly 10-fold higher than in the US 
(Table 1 and [16]). The reasons for 
this substantial discrepancy are elusive, 
but may in part be attributed to the 
notorious difﬁ  culty of assessing with 
accuracy the impact of inﬂ  uenza on 
children. There is a particularly high 
background rate of acute respiratory 
illnesses caused by other respiratory 
pathogens in this age group. 
Unfortunately, the authors did not 
reexamine this apparent discrepancy in 
the new, larger citywide study published 
this month [4]—so the question of a 
true regional difference in pediatric 
rates of inﬂ  uenza-related pneumonia 
hospitalizations remains unresolved.
    The Need for More Inﬂ  uenza 
Studies in Tropical Regions 
    Many research questions about 
inﬂ  uenza in tropical regions remain 
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unanswered. For instance, Hong 
Kong is a wealthy subtropical city, with 
a higher per-capita gross domestic 
product than Australia or New Zealand. 
Thus, the present Hong Kong study 
cannot inform us about the impact of 
inﬂ  uenza in poor tropical countries, 
where the severity of infections is 
likely compounded by malnutrition, 
limited supplies of antibiotics to treat 
secondary bacterial infections, and 
limited access to hospital care. 
    Modeling the inﬂ  uenza burden 
in tropical countries relies on good-
quality virus surveillance data. And 
because of large year-to-year variations 
in the impact of inﬂ  uenza, modeling 
also depends on the availability of 
several years’ worth of data. Since 
inﬂ  uenza surveillance efforts were only 
recently initiated in tropical countries, 
studies of the inﬂ  uenza burden are 
generally of short duration (ﬁ  ve years 
in the study by Peiris et al. [4]). The 
information generated so far during 
a period mostly dominated by more 
pathogenic inﬂ  uenza A (H3N2) 
viruses may not reﬂ  ect the average 
inﬂ  uenza experience in Hong Kong 
[13]. An additional shortcoming of 
the virus-driven modeling approach 
is that it cannot study past epidemics 
and pandemics for which no viral 
surveillance data was collected. 
Furthermore in this approach, deaths 
or hospitalizations attributed to 
inﬂ  uenza are directly proportional 
to the intensity of virus activity, and 
therefore, week-to-week variations in 
virus isolation rates should truly reﬂ  ect 
changes in disease prevalence and not 
sampling error. Laboratory surveillance 
needs to be strengthened before 
modeling of disease burden becomes 
feasible in most tropical countries [1].
DOI: 10.1371/journal.pmed.0030089.g001 
  Figure 1.   Comparison of Inﬂ  uenza Seasonal Patterns in Temperate and Tropical Countries in the Americas (From Lat +39˚N to −35˚S)
      The latitude of the capital city is indicated for each country in the legend. 
    (A) Weekly distribution of inﬂ  uenza laboratory isolates (from week 1 to week 52; weekly frequency (  y -axis) is calculated as the weekly number of isolates 
divided by the annual number of isolates). 
    (B) Weekly numbers of isolates were aggregated over four-week periods to show a (nearly) monthly distribution of inﬂ  uenza circulation. Each color 
represents a different month (color bar on the right). Note the transition in seasonal patterns from north to south, ranging from marked seasonal winter 
activity centered around January in the US, to uniform circulation throughout the year in Columbia and again, strong winter epidemics center around 
July in Argentina.
  Inﬂ  uenza viral surveillance data compiled from WHO Flunet. 
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    Finally, more studies are needed to 
elucidate inﬂ  uenza seasonal patterns 
across a large range of latitudes, 
representing several tropical countries 
in both hemispheres. Of particular 
interest is the long-standing question 
of persistence: does inﬂ  uenza persist 
in temperate countries all year long 
(through undetectable chains of 
transmission in summer) or is it 
reintroduced from the Tropics each 
year at the beginning of winter? 
A combination of enhanced virus 
surveillance and sequence analysis of 
the viral genome of circulating strains 
is an important avenue for future 
research to address this question, 
and Hong Kong may be an essential 
sampling site in this respect. 
    Resolving this question is of 
paramount importance to vaccine 
composition and inﬂ  uenza control 
in tropical regions. Because of year-
round inﬂ  uenza activity, it is not clear 
whether the Northern Hemisphere or 
Southern Hemisphere recommended 
composition should be used, and what 
the optimal timing for the vaccination 
campaign would be. Indeed, the 
inﬂ  uenza vaccination strategy may 
have to be tailored to each individual 
tropical region, based on local 
prevalence, timing, cycling of inﬂ  uenza 
strains, and how they match the strains 
circulating in temperate areas. 
    Who Should Be Vaccinated?
    Peiris and colleagues’ study implies 
that inﬂ  uenza is an underappreciated 
public health issue in tropical regions—
indeed, inﬂ  uenza vaccine coverage is 
far lower in Hong Kong than in most 
developed countries with a temperate 
climate [17]. The authors argue for 
wider use of inﬂ  uenza vaccines in the 
elderly and chronically ill; however, this 
strategy has not been associated with 
any measurable reduction in inﬂ  uenza-
related mortality in the US [8], likely in 
part because of reduced responsiveness 
to the vaccine in the elderly [18]. In 
the US and Europe, moving toward 
universal vaccination is now being 
discussed as a strategy to further reduce 
the impact of inﬂ  uenza in high-risk 
groups by indirect means. Vaccinating 
schoolchildren may be especially 
beneﬁ  cial in this regard, since they 
are the main spreader of inﬂ  uenza in 
schools and households [19–21]. If the 
unusually high impact of inﬂ  uenza in 
young Hong Kong children is real, then 
this would be an additional argument 
for vaccinating schoolchildren in 
this city, as preschoolers are likely to 
contract inﬂ  uenza from their older 
siblings [22].   
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 Table 1.  Comparison of the Average Annual Burden of Inﬂ  uenza on Hospitalization and Death in Recent Years in Hong Kong and the US   




Hong Kong Annual 
Hospitalizations/100,000
All Causes Pneumonia 
and Inﬂ  uenza
All Causes Pneumonia 
and Inﬂ  uenza
All Causes Pneumonia 
and Inﬂ  uenza
All Causes Pneumonia 
and Inﬂ  uenza
All ages 15a 2.9a 16c 4.1c 115d 52d 78e 29e
20b 3.0b
Under 5 years old 1.3a 0.3a 114d 26d 1,400g
1.3b 0.2b 300f
Under 65 years old 3.0a 0.4a 56d 23d 45e 18e
4.2b 0.5b 26h
Over 65 years old 100a 22a 136c 39c 621d 300d 267e 102e 
132b 22b 260h 303i 130i
    In the US, the inﬂ  uenza season runs from November to April. In Hong Kong, the inﬂ  uenza season matches the calendar year, since there is year-round circulation of inﬂ  uenza and seasonal patterns are less deﬁ  ned.
  aTraditional seasonal regression model applied to US national vital statistics, 1980–2001, as in [8].
  bModel guided by viral surveillance data [10].
  cModel guided by viral surveillance data [13].
  dModel guided by viral surveillance data [9].
  eModel guided by viral surveillance data [4].
  fCohort study [23].
  gCohort study [16].
  hTraditional seasonal regression model [2].
  iModel guided by viral surveillance data [14].
  DOI:  10.1371/journal.pmed.0030089.t001 
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